iRadimed Corporation (NASDAQ:IRMD) Receives Average Recommendation of “Moderate Buy” from Brokerages

iRadimed Corporation (NASDAQ:IRMD) has earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $87.3333.

IRMD has been the subject of a number of recent analyst reports. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 26th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research note on Monday. Zacks Research upgraded shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Lake Street Capital reaffirmed a “buy” rating and issued a $100.00 target price on shares of iRadimed in a research report on Monday, November 3rd. Finally, Roth Capital set a $90.00 target price on shares of iRadimed in a research note on Friday, October 31st.

Insider Buying and Selling

In other news, CFO John Glenn sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $97.29, for a total value of $1,459,350.00. Following the completion of the transaction, the chief financial officer owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. This represents a 67.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $96.73, for a total value of $483,650.00. Following the sale, the chief executive officer owned 2,287,500 shares in the company, valued at $221,269,875. This represents a 0.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 65,000 shares of company stock worth $5,548,150 in the last quarter. Company insiders own 36.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. CWM LLC boosted its stake in iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 211 shares in the last quarter. Quarry LP purchased a new stake in shares of iRadimed in the 3rd quarter worth approximately $40,000. State of Alaska Department of Revenue bought a new position in iRadimed during the 3rd quarter valued at approximately $47,000. Tower Research Capital LLC TRC raised its stake in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares during the last quarter. Finally, Spire Wealth Management bought a new stake in iRadimed in the second quarter worth $60,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Stock Performance

Shares of IRMD stock opened at $97.04 on Friday. The company has a market capitalization of $1.23 billion, a P/E ratio of 58.81 and a beta of 1.06. iRadimed has a fifty-two week low of $47.48 and a fifty-two week high of $98.44. The stock has a 50 day moving average price of $88.24 and a two-hundred day moving average price of $73.89.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, topping the consensus estimate of $0.43 by $0.04. The company had revenue of $21.20 million for the quarter, compared to the consensus estimate of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. As a group, equities analysts predict that iRadimed will post 1.66 earnings per share for the current year.

iRadimed Announces Dividend

The company also recently disclosed a special dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Wednesday, December 17th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s payout ratio is presently 41.21%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.